# US 2026/0242390 A1 · Total syntheses of portimine a and analogues thereof as small molecule modulators of nmd3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242390 A1
- Document ID: US20260242390A1
- Status: Published application
- Kind: A1
- Application number: 19/147,893
- Filed: 2024-01-17
- Published: 2026-08-20
- Earliest claimed: 2023-01-17
- Assignees: The Scripps Research Institute
- Applicants: The Scripps Research Institute
- Inventors: Phil S. BARAN; Christopher PARKER; Luke L. LAIRSON; Junchen TANG; Weichao LI; Francisco MARTINEZ; Tzu-Yuan CHIU
- Web page: https://patentgrep.com/patent/US20260242390A1

## CPC

- C07D 491/22: in which the condensed system contains four or more hetero rings
- C07C 269/06: by reactions not involving the formation of carbamate groups
- C07C 303/30: by reactions not involving the formation of esterified sulfo groups
- C07D 209/54: Spiro-condensed
- C07D 301/02: Synthesis of the oxirane ring
- C07D 317/14: with substituted hydrocarbon radicals attached to ring carbon atoms
- C07F 5/025: {Boronic and borinic acid compounds}
- C07F 7/1804: {Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896)}
- C07F 7/1872: {Preparation; Treatments not provided for in C07F7/20}
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are enantioselective methods of making known cyclic imine (CI) toxins and analogues thereof as small molecule inhibitors of NMD3 with selective and potent anti-cancer activity.

## Claims

### Claim 1

A process for preparing Portimine A (1),
wherein the process comprises the Diels-Alder cycloaddition of Compound (8) to form Compound (10):

### Claim 2 (depends on 1)

The process of claim 1, further comprising the alcohol oxidation of Compound (10), subsequent Grignard addition, and Dess-Martin oxidation to form Compound (11):

### Claim 3 (depends on 2)

The process of claim 2, further comprising the cyclization of Compound (11) to form Compound (12):

### Claim 4

A process of preparing Compound (13) from (S)-solketal, comprising the following steps:

### Claim 5 (depends on 4)

The process of claim 4, further comprising the following steps:

### Claim 6 (depends on 5)

The process of claim 5, further comprising the following steps:

### Claim 7 (depends on 3)

The process of claim 3, further comprising the transmetallation of Compound (13) and conjugate addition to Compound (12) to form Compound (7):

### Claim 8 (depends on 7)

The process of claim 7, further comprising the conversion of compound (7) to the N-protected imine Compound (31):

### Claim 9 (depends on 8)

The process of claim 8, further comprising Mo-catalyzed ring-closing alkyne metathesis to form Compound (15):

### Claim 10 (depends on 9)

The process of claim 9, further comprising ring formation and oxidation of Compound (15) to form Compound (16):

### Claim 11 (depends on 10)

The process of claim 10, further comprising the reduction of Compound (16) to Compound (32):

### Claim 12 (depends on 11)

The process of claim 11, further comprising ring-chain tautomerism of Compound (32) to form Compound (19):

### Claim 13 (depends on 12)

The process of claim 12, further comprising the silylation and oxidation of Compound (19) to form Compound (20):

### Claim 14 (depends on 13)

The process of claim 13, further comprising the conversion of Compound (20) to Compound (21):

### Claim 15 (depends on 14)

The process of claim 14, further comprising Pd-catalyzed vinylation of Compound (21) to form Compound (22):

### Claim 16 (depends on 15)

The process of claim 15, further comprising the Dess-Martin oxidation of Compound (22) and subsequent hydrolysis to form Compound (2):

### Claim 17 (depends on 16)

The process of claim 16, further comprising the reduction of Compound (2) to form Portimine A (1):

### Claim 18

A process for preparing Portimine A (1),
wherein the process comprises the reduction of Compound (2) to form Portimine A (1):

### Claim 19

A compound having the structure of Formula (2):
or a scalemic or racemic mixture of.

### Claim 20 (depends on 19)

A process of preparing the compound of claim 19, comprising the Dess-Martin oxidation of Compound (22) and subsequent hydrolysis to form Compound (2)
